Arcutis Biotherapeutics, Inc.
ARQT
Classifica tra le azioni
#3977
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Prezzo delle azioni
$32.88
Capitalizzazione di mercato
$4.13B
Variazione (1 giorno)
3.11%
Variazione (1 anno)
57.49%
Paese
US
Scambia Arcutis Biotherapeutics, Inc. (ARQT)
Categoria
Healthcare
Ricavi di Arcutis Biotherapeutics, Inc. (ARQT)
Ricavi nel Jun 2026 TTM: $463.98M
Secondo gli ultimi rapporti finanziari di Arcutis Biotherapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $463.98M. Nel 2023, l'azienda ha registrato ricavi di $59.61M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $3.69M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Arcutis Biotherapeutics, Inc. da 2017 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $463.98M | 136.07% |
| 2024 | $196.54M | 229.74% |
| 2023 | $59.61M | 1,517.09% |
| 2022 | $3.69M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 2,620.87% |
US
|
|
| $2.23B | 380.19% |
US
|
|
| $15.74B | 3,293.31% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,197.74% |
NL
|
